Article
How Biosimilars Could Impact the Future of Cancer Care
Rowena Schwartz, PharmD, BCOP, associate professor of pharmacy at the University of Cincinnati, joins Deborah Struth, MSN, RN, ONS research associate, to discuss the rapid emergence of biosimilar products on the market and how they’ll impact the treatment of cancer. Learn more about what biosimilars are, their approval processes, and the important things to know for practice.
Related Topics
You May Also Like
Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
Article